UY28528A1 - Nuevos compuestos - Google Patents

Nuevos compuestos

Info

Publication number
UY28528A1
UY28528A1 UY28528A UY28528A UY28528A1 UY 28528 A1 UY28528 A1 UY 28528A1 UY 28528 A UY28528 A UY 28528A UY 28528 A UY28528 A UY 28528A UY 28528 A1 UY28528 A1 UY 28528A1
Authority
UY
Uruguay
Prior art keywords
alkyl
6nr4r5
cyano
compounds
new compounds
Prior art date
Application number
UY28528A
Other languages
English (en)
Inventor
Stefan Berg
Sven Hellberg
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of UY28528A1 publication Critical patent/UY28528A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

La presente invención se refiere a nuevos compuestos de fórmula Ia o Ib P representa un anillo heteroaromático de 5 o 6 miembros que contiene uno o dos heteroátomos seleccionados independientemente de N, O y S de lo cuales al menos un heteroátomo es nitrógeno; R1 es hidrógeno; R2 se selecciona de: alquiloC1-6, ciano, hal´geno, (CO)OR10, y CONR10R11 ; R3 se selecciona de:alquiloC1-6, ciano, nitro, (CO)OR4, alquiloC1-6NR4R5, OalquiloC2-6NR4R5, CONR4R5, y (SO2)NR4R5; m es 0,1,2,3 o 4; n es 0,1,2,3o4; como una base libre o una sal de los mismos, un proceso para su preparación y nuevos compuestos intermedios utilizados en losmismos, formulaciones farmacéuticas que contienen dichos compuestos terapéuticamente activos y el uso de dichos compuestos activos en terapia.
UY28528A 2003-09-24 2004-09-21 Nuevos compuestos UY28528A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0302546A SE0302546D0 (sv) 2003-09-24 2003-09-24 New compounds

Publications (1)

Publication Number Publication Date
UY28528A1 true UY28528A1 (es) 2005-04-29

Family

ID=29212538

Family Applications (1)

Application Number Title Priority Date Filing Date
UY28528A UY28528A1 (es) 2003-09-24 2004-09-21 Nuevos compuestos

Country Status (13)

Country Link
US (1) US7683067B2 (es)
EP (1) EP1667990A2 (es)
JP (1) JP2007506734A (es)
CN (1) CN1886397A (es)
AR (1) AR045793A1 (es)
AU (1) AU2004273771B2 (es)
BR (1) BRPI0414632A (es)
CA (1) CA2538381A1 (es)
MX (1) MXPA06003195A (es)
SE (1) SE0302546D0 (es)
TW (1) TW200526627A (es)
UY (1) UY28528A1 (es)
WO (1) WO2005027823A2 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0200979D0 (sv) * 2002-03-28 2002-03-28 Astrazeneca Ab New compounds
WO2007025177A2 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258357A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
US7985756B2 (en) 2005-10-21 2011-07-26 Braincells Inc. Modulation of neurogenesis by PDE inhibition
WO2007053596A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
JP2009525325A (ja) * 2006-02-02 2009-07-09 アストラゼネカ・アクチエボラーグ ２−ヒドロキシ−３−［５−（モルホリン−４−イルメチル）ピリジン−２−イル］１ｈ−インドール−５−カルボニトリルの遊離塩基又は塩としての医薬用途
SA07280004B1 (ar) * 2006-02-02 2011-10-29 استرازينيكا ايه بي ملح سترات من مركب 2- هيدروكسي –3- [5- (مورفولين –4- يل ميثيل) بيريدين –2- يل] 1h- إندول –5- كربونيتريل سترات
EP1991539A4 (en) * 2006-02-28 2010-08-25 Astrazeneca Ab NEW SALTS OF INDIGENOUS DERIVATIVES AND THEIR USE IN MEDICINE
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
WO2007120102A1 (en) * 2006-04-19 2007-10-25 Astrazeneca Ab New substituted oxindole derivatives
WO2007134136A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US20090291982A1 (en) * 2008-05-22 2009-11-26 Astrazeneca Ab New Substituted Oxindole Derivative 352
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
TW201040191A (en) * 2009-03-27 2010-11-16 Abbott Gmbh & Co Kg Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
EP2377850A1 (en) * 2010-03-30 2011-10-19 Pharmeste S.r.l. TRPV1 vanilloid receptor antagonists with a bicyclic portion
WO2012084855A2 (de) 2010-12-21 2012-06-28 Bayer Cropscience Ag Verfahren zur herstellung von triazinylsubstituierten oxindolen
CA2945263A1 (en) 2014-04-09 2015-10-15 Christopher Rudd Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity
US20220133740A1 (en) 2019-02-08 2022-05-05 Frequency Therapeutics, Inc. Valproic acid compounds and wnt agonists for treating ear disorders

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5940149B2 (ja) * 1977-11-09 1984-09-28 大塚製薬株式会社 オキシインド−ル誘導体
US5565580A (en) 1994-01-27 1996-10-15 Neurosearch A/S Glutamate Antagonists
TW574214B (en) 1994-06-08 2004-02-01 Pfizer Corticotropin releasing factor antagonists
GB9707800D0 (en) 1996-05-06 1997-06-04 Zeneca Ltd Chemical compounds
US6569868B2 (en) * 1998-04-16 2003-05-27 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
WO2000071129A1 (en) 1999-05-21 2000-11-30 Bristol-Myers Squibb Company Pyrrolotriazine inhibitors of kinases
JP2003511378A (ja) 1999-10-07 2003-03-25 アムジエン・インコーポレーテツド トリアジン系キナーゼ阻害薬
UA75054C2 (uk) 1999-10-13 2006-03-15 Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг Заміщені в положенні 6 індолінони, їх одержання та їх застосування як лікарського засобу
US6455525B1 (en) 1999-11-04 2002-09-24 Cephalon, Inc. Heterocyclic substituted pyrazolones
CA2417277A1 (en) 2000-07-27 2002-02-07 F. Hoffmann-La Roche Ag 3-indolyl-4-phenyl-1h-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3.beta.
CA2425771A1 (en) 2000-10-13 2002-04-18 Christopher G. Boissard Selective maxi-k- potassium channel openers functional under conditions of high intracellular calcium concentration, methods and uses thereof
SE0104341D0 (sv) * 2001-12-20 2001-12-20 Astrazeneca Ab New use
SE0104340D0 (sv) * 2001-12-20 2001-12-20 Astrazeneca Ab New compounds
ATE367387T1 (de) * 2001-12-21 2007-08-15 Astrazeneca Ab Verwendung von oxindolderivaten zur behandlung von mit demenz in zusammenhang stehenden krankheiten, alzheimer-krankheit und mit glycogensynthasekinase-3 assoziierten leiden
TW200301123A (en) 2001-12-21 2003-07-01 Astrazeneca Uk Ltd New use
SE0200979D0 (sv) 2002-03-28 2002-03-28 Astrazeneca Ab New compounds
US6987110B2 (en) * 2002-06-05 2006-01-17 Janssen Pharmaceutica N.V. Substituted pyrrolines as kinase inhibitors

Also Published As

Publication number Publication date
WO2005027823A2 (en) 2005-03-31
TW200526627A (en) 2005-08-16
AR045793A1 (es) 2005-11-16
BRPI0414632A (pt) 2006-11-07
JP2007506734A (ja) 2007-03-22
SE0302546D0 (sv) 2003-09-24
AU2004273771A1 (en) 2005-03-31
MXPA06003195A (es) 2006-06-23
WO2005027823A3 (en) 2005-06-02
CA2538381A1 (en) 2005-03-31
US7683067B2 (en) 2010-03-23
CN1886397A (zh) 2006-12-27
AU2004273771B2 (en) 2008-11-06
US20080275041A1 (en) 2008-11-06
EP1667990A2 (en) 2006-06-14

Similar Documents

Publication Publication Date Title
UY28528A1 (es) Nuevos compuestos
BR0206433A (pt) Composto, composição farmacêutica, processo para a prepapação de um composto, e, uso de um composto
UY27740A1 (es) Nuevos compuestos
AR004219A1 (es) Nuevos derivados de quinazolina, procedimientos para su preparacion, composiciones que los contienen y su uso en la preparacion de medicamentos,particularmente en el tratamiento de trastornos inflamatorios
AR016762A1 (es) Compuestos del acido 4-bromo o 4-yodo fenilamino benzohidroxamico, formulaciones farmaceuticas y uso del mismo
ES2112830T3 (es) 4-pirimidinaminas y -pirimidindiaminas sustituidas en n, un procedimiento para su preparacion y su uso como medicamentos.
BR0314113A (pt) Derivados de amino propanol
DK1206467T3 (da) N-heterocykliske derivater som NOS-inhibitorer
BRPI0410760A (pt) compostos, processo para fabricação dos mesmos, composições farmacêuticas e uso deste compostos
BRPI0409227B8 (pt) "composto, composição farmacêutica, uso de um composto e processo para a preparação de um composto de fórmula (i)"
BRPI0514750A (pt) derivados amida de 7-amino-3-fenil-diidropirimido[4, 5-d]pirimidinonas, sua fabricação e uso como inibidores de proteìna cinase
UY29246A1 (es) Nuevos compuestos
ES2193921T3 (es) Compuestos de sulfamoilheteroaril-pirazol como agentes antinflamatorios/analgesicos.
ES2168737T3 (es) Inhibidores de la oxido nitrico sintasa.
BR0317268A (pt) Compostos ativadores da pirazina e da piridina glucoquinase 5-substituìda, composição farmacêutica, uso e processo de preparação dos mesmos
AR029301A1 (es) Compuestos derivados de biarilo, metodos para su preparacion composiciones que los contienen, su uso como agonistas en receptores beta-adreno-receptores atipicos
BR0309546A (pt) Composto, composição farmacêutica que compreende o mesmo, processo para a sua preparação e utilização e método para tratamento profilático ou terapêutico de diabetes do tipo ii
BR0314379A (pt) Quinazolinonas espirocondensadas e a sua utilização como inibidores de fosfodiesterase
PA8539801A1 (es) Derivados del ácido isoftálico como inhibidores de metaloproteinasas de la matriz
BR0310077A (pt) Novos compostos e sua utilização
BRPI0408353A (pt) composto, composição farmacêutica, métodos para o tratamento de neoplasias suscetìveis e para o tratamento de infecções virais, e, uso de um composto
UY28979A1 (es) Derivados de hidrocloruros de 3-carboxamida, composiciones farmacéuticas que los contienen, procedimiento de preparación y su uso, útiles como inhibidores selectivos de gsk3
BRPI0407695A (pt) compostos, processo para a preparação de um composto, composições farmacêuticas que compreendem o composto, utilização dos compostos e processo de tratamento para diabetes do tipo 2
UY29739A1 (es) Derivados de amidas o sales farmacéuticamente aceptables de los mismos, procesos de preparaciones farmacéuticas conteniéndolos y aplicaciones
BR0308765A (pt) Compostos (4,2-dissubstituìdo-tiazol-5-il)amina como inibidores de pde7

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20150604